Skip to main content
. Author manuscript; available in PMC: 2022 Aug 17.
Published in final edited form as: Nat Cell Biol. 2022 Feb 17;24(3):373–383. doi: 10.1038/s41556-022-00848-5

Extended Data Fig. 9: Inhibiting LSD1 impedes the proliferation of human cancer cells with active YAP/TAZ.

Extended Data Fig. 9:

a, LSD1 knockdown efficiency was evaluated by RT-qPCR in HLE, SNU-886 and MDA-MB-231 cells 2 days post doxycycline (Dox) treatment. Each cell line was tested with two different Dox inducible shRNAs (shLSD1 #1 and shLSD1 #2). Data are represented as mean ± SD, n = 3, unpaired two-tailed Student’s t-test. b, HLE cells carrying shLSD1 #2 were treated with 1 μg/mL of Dox. Relative cell number was measured. Data are represented as mean ± SD, n = 5, two-way ANOVA. c, SNU-886 cells carrying shLSD1 #2 were treated with 1 μg/mL of Dox. Relative cell number was measured. Data are represented as mean ± SD, n = 6, two-way ANOVA. d, MDA-MB-231 cells carrying shLSD1 #2 were treated with 1 μg/mL of Dox. Relative cell number was measured. Data are represented as mean ± SD, n = 6, two-way ANOVA. e, ES-2 cells were treated with different concentrations of LSD1 inhibitor SP-2577. Relative cell number was measured. Data are represented as mean ± SD, n = 6, two-way ANOVA.